CARLOS MANUEL
PANIZO SANTOS
Universidad de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Navarra (50)
2023
-
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study
British Journal of Haematology, Vol. 202, Núm. 4, pp. 776-784
-
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Blood Advances, Vol. 7, Núm. 17, pp. 4926-4935
-
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Nature Medicine, Vol. 29, Núm. 3, pp. 632-645
-
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
Journal for immunotherapy of cancer, Vol. 11, Núm. 2
2022
-
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100
-
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
Haematologica, Vol. 107, Núm. 11, pp. 2675-2684
2021
-
Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death
Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285
2020
-
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Blood, Vol. 135, Núm. 13, pp. 996-1007
-
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6
Pharmacology Research and Perspectives, Vol. 8, Núm. 5
-
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
British Journal of Haematology, Vol. 188, Núm. 5, pp. 661-673
2019
-
Burkitt-like lymphoma with 11q aberration: A germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma
Haematologica, Vol. 104, Núm. 9, pp. 1822-1829
-
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Leukemia
-
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas
Blood, Vol. 133, Núm. 22, pp. 2401-2412
-
The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma
Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187
2018
-
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
The Lancet, Vol. 391, Núm. 10121, pp. 659-667
-
Post-transplant lymphoproliferative disease after liver transplantation
Revista Espanola de Enfermedades Digestivas
-
Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia
Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73
-
Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
Oncotarget, Vol. 9, Núm. 64, pp. 32383-32399
-
Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in b lymphoid neoplasms
Haematologica, Vol. 103, Núm. 6, pp. 1065-1072
-
Update on posttransplant lymphoproliferative disease
Current Opinion in Nephrology and Hypertension, Vol. 27, Núm. 6, pp. 440-444